AVANIR Pharmaceuticals Invites Investors to Its Fourth Quarter and Fiscal 2005 Conference Call on December 5, 2005

SAN DIEGO, Nov 30, 2005 (BUSINESS WIRE) -- AVANIR Pharmaceuticals (AMEX:AVN) will webcast its quarterly conference call on Monday, December 5, 2005, at 1:30 p.m. Pacific/4:30 p.m. Eastern. The call will be webcast live through AVANIR's corporate website at www.avanir.com and will feature Eric Brandt, President and Chief Executive Officer, and Gregory P. Hanson, Vice President and Chief Financial Officer. A press release announcing the fourth fiscal quarter and the 2005 year end financial results will be released at market close the same day.

It is recommended that you go to AVANIR's website at least 10 minutes in advance of the webcast to download any applicable software. For those who cannot listen to the live broadcast, the online replay will be available for 90 days, and a phone replay will be available through December 9, 2005, by dialing 800-642-1687 (domestic) and 706-645-9291 (international) and entering the passcode 2480112.

AVANIR Pharmaceuticals is focused on developing and commercializing novel therapeutic products for the treatment of chronic diseases. AVANIR's product candidates address therapeutic markets that include central nervous system and cardiovascular disorders, inflammation and infectious disease. AVANIR recently submitted to the FDA its New Drug Application for Neurodex(TM) for the treatment of pseudobulbar affect. Additionally, AVANIR has initiated a phase III clinical trial of Neurodex(TM) for the treatment of diabetic neuropathic pain. AVANIR has active collaborations with two international pharmaceutical companies: Novartis International Pharmaceutical Ltd. for the treatment of inflammatory disease and AstraZeneca UK Limited for the treatment of cardiovascular disease. The Company's first commercialized product, Abreva(R), is marketed in North America by GlaxoSmithKline Consumer Healthcare and is the leading over-the-counter product for the treatment of cold sores. Further information about AVANIR can be found at www.avanir.com.

The information contained in this press release, including any forward-looking statements contained herein, should be reviewed in conjunction with the company's most recent Annual Report on Form 10-K and other publicly available information regarding the company. Copies of such information are available from the company upon request. Such publicly available information sets forth many risks and uncertainties related to the company's business and technology. Forward-looking statements often contain such words like "estimate," "anticipate," "believe," "plan" or "expect". The company disclaims any intent or obligation to update these forward-looking statements. Final review decisions made by the FDA and other regulatory agencies concerning clinical trial results are unpredictable and outside the influence and/or control of the company.

SOURCE: AVANIR Pharmaceuticals

AVANIR Pharmaceuticals (Investor Relations)
Patrice Saxon, 858-622-5202
psaxon@avanir.com